Characterising the immunopeptidome to improve immunotherapy in head and neck cancer
Tag: New treatment
Dr Jyoti Choudhary and Prof Kevin Harrington
Miriam Melake (pictured)
Length of project:
Oracle Cancer Trust
The Institute of Cancer Research
Immunotherapy represents a revolutionary approach to treat cancer, but many human cancers are resistant to immunotherapy, for reasons poorly understood.
Many head and neck cancer patients develop recurrent disease and there is a pressing need to find new and better treatments to eradicate it. Immunotherapy has proven promising for head and neck cancer, but we need to understand how it works so that we can improve it and provide effective treatment to the majority of patients for whom it does not work at present.
In this project, we will characterise the proteins shown on the surface of cancer cells for inspection by the immune system (the so-called immunopeptidome) in model cell lines and from patient samples. These molecules provide direct communication between the tumour and immune cells and the nature of the immunopeptidome repertoire in different tumours is thought to play a key role in determining whether, or not, immunotherapy will be effective.
This project will use immunoproteomics to identify molecular markers of tumour cell sensitivity and resistance to killing by cytotoxic T cell, the effectors of anti-tumour immunity.
The resulting data will provide new information about HNC that will help in the development of new immunotherapies and provide patient classification to enable personalised therapy.
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.